Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach
Ardelyx (NASDAQ:ARDX) executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to invest in its pipeline and positioning the business for sustainable profitability. Chief Financial Officer Sue Hohenleitner said Ardelyx expects its two commercial products to generate more than […]
4 Jun 12:04 · The Markets Daily